On May 1999, Houghten Pharmaceuticals (Nasdaq:HPIP) changed its name to Trega Biosciences. Trega Biosciences, Inc. is focused on accelerating drug discovery from disease targets to clinical candidates through its iDiscovery technologies. Such technologies include the IDEA (In Vitro Determination for the Estimation of ADME (absorption, distribution, metabolism and excretion)) computerized predictive models for, among other things, the prediction and selection of compounds with essential drug-like characteristics for further development and Chem.Folio combinatorial libraries for screening and optimization of potential drug candidates. On March 14, 2001 Trega Biosciences merged with LION Bioscience AG (LEON).
